Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis ...Middle East

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody,...

Hence then, the article about keymed biosciences announces approval of stapokibart for the treatment of chronic rhinosinusitis with nasal polyposis was published today ( Monday 23/12/2024 - 05:56 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis )

Also on site :

• Art’s Angle: Three-Ring Circus
• ‘The Comeback’ took on Hollywood long before ‘The Studio.’ Now, Valerie Cherish will have her curtain call
• Why do animals have different pupil shapes?